Company

Heidelberg Pharma AG

Headquarters: Ladenburg, Germany

Employees: 85

CEO: Dr. Jan Schmidt-Brand

Market Cap

€125.5 Million

EUR as of July 1, 2024

US$134.7 Million

Market Cap History

Heidelberg Pharma AG market capitalization over time

Evolution of Heidelberg Pharma AG market cap in the past 5 years

Market capitalizations are calculated from the opening stock price at the beginning of each month.

Market Cap History of Heidelberg Pharma AG

Detailed Description

Heidelberg Pharma AG, a biopharmaceutical company, focuses on oncology and antibody targeted amanitin conjugates (ATAC) in Germany, other European countries, the United States, and internationally. It is developing HDP-101 for the treatment of multiple myeloma; HDP-102 for the treatment of non-Hodgkin lymphoma; HDP-103, an ATAC candidate to treat prostate cancer; and CDXX-ATACs, a candidate for the treatment of solid/hematological tumors. The company is also developing MGTA-ATACs for HSCs, conditioning programs for blood cancers, and genetic diseases; TAK-ATACs for oncology treatment; and EMR-ATAC for the treatment of solid tumors. In addition, it provides preclinical research services in the fields of cancer, and inflammatory and autoimmune diseases. The company was formerly known as Wilex AG and changed its name to Heidelberg Pharma AG in October 2017. Heidelberg Pharma AG was founded in 1997 and is based in Ladenburg, Germany.

Top 1-year algo backtest: +265.99%

$10,000 in October 2023 would now be $36,599 by following this algorithm daily at market close.

Use AI to boost your investing & swing trading, now!

Try Disfold DeepFinance FREE

Stocks & Indices

Heidelberg Pharma AG has the following listings and related stock indices.


Stock: FSX: HPHA wb_incandescent

Stock: XETR: HPHA wb_incandescent

Details

Headquarters:

Gregor-Mendel-Strasse 22

Ladenburg, 68526

Germany

Phone: 49 6203 1009 0

Fax: 49 6203 1009 19